Three Selective Androgen Receptor Modulators with Different Evidence Profiles
MK-2866, AC-262 and ACP-105 are three synthetic, nonsteroidal selective androgen receptor modulators investigated within androgen receptor research. They share a broad pharmacological category, but they are not identical compounds and should not be treated as interchangeable versions of the same molecule.
MK-2866 is commonly known as Ostarine and is associated with the developmental name Enobosarm or GTx-024. It has the largest evidence base of the three compounds and has progressed from laboratory research into controlled human trials. AC-262 is more precisely identified as AC-262,536 and is commonly called Accadrine. Its published evidence centres on receptor assays and short animal studies. ACP-105 is another experimental nonsteroidal androgen receptor ligand. BioPlex presents it under the product name Androxepen, although ACP-105 remains its most important scientific identifier.
The three compounds are included within one BioPlex research set because they provide different ways to investigate selective androgen receptor signalling. Their inclusion in the same set does not demonstrate that they work better together, establish an effective combination or justify transferring findings from one compound to another.
The strongest scientific use of the set is comparative. Researchers can examine how three different chemical structures interact with the same broad receptor system, how their reported pharmacology differs and why one compound has reached human trials while the other two remain supported almost entirely by preclinical evidence.
What Is the Androgen Receptor?
The androgen receptor is an intracellular protein belonging to the nuclear receptor family. Its natural ligands include testosterone and dihydrotestosterone. When a suitable molecule reaches a cell and binds to the receptor, the receptor can change conformation, interact with regulatory proteins and influence the transcription of androgen responsive genes.
This pathway is relevant to numerous tissues. Androgen receptor signalling is involved in skeletal muscle, bone, reproductive tissues, skin, the nervous system and endocrine feedback. Activating the receptor therefore cannot be reduced to a single effect such as increasing muscle tissue.
Selective androgen receptor modulator research attempts to determine whether different ligands can produce useful patterns of receptor activity across tissues. The word selective does not mean that a compound only acts in skeletal muscle or that it is free from endocrine, reproductive, cardiovascular or hepatic consequences. Selectivity is a relative pharmacological concept established by comparing responses across defined assays and tissues.
Two compounds can bind to the same receptor but produce different experimental outcomes. Chemical structure, binding affinity, intrinsic activity, receptor concentration, cellular coactivators, corepressors, metabolism and exposure all influence the response. This is why the three compounds in this set require independent characterisation.
MK-2866 Ostarine as the Best Characterised Compound
MK-2866 is the most extensively investigated component of the set. It is widely known as Ostarine, while Enobosarm and GTx-024 appear frequently in clinical literature. The compound was developed as an orally active nonsteroidal selective androgen receptor modulator and has been investigated in relation to lean body mass, physical function, muscle wasting and other androgen receptor dependent processes.
A double blind, placebo controlled Phase II trial published in 2011 examined GTx-024 in 120 healthy men over 60 and postmenopausal women. Participants received placebo or different quantities of the compound for 12 weeks. Total lean body mass measured using dual energy X ray absorptiometry was the primary endpoint, while physical function, body weight, insulin resistance and safety were also investigated.
The researchers reported a dose related increase in total lean body mass, with the 3 mg group showing a statistically significant improvement compared with placebo. Stair climb performance also improved in that group. These results provide controlled human evidence that Enobosarm can influence lean mass and selected functional measurements under a defined clinical protocol.
The study does not demonstrate unrestricted muscle growth, athletic performance enhancement or the safety of unstudied exposures. The participants were older adults rather than trained young athletes, the investigation lasted 12 weeks and the quantities studied cannot be translated automatically into other settings. The authors were also employees of the company developing the compound and held company stock or options, making independent replication particularly important.
Later clinical development produced a more complicated picture. Enobosarm was investigated in patients experiencing muscle wasting associated with non small cell lung cancer. Lean body mass signals were reported, but the clinical programme did not establish consistent improvement across the required physical function endpoints. An increase in lean mass is not automatically equivalent to a meaningful increase in strength, mobility, independence or clinical outcome.
This difference between body composition and function is central to interpreting MK-2866 research. Imaging can identify a change in lean tissue, but it cannot by itself show that the tissue produces greater force, improves endurance or benefits long term health. Functional testing, adverse event monitoring and clinically meaningful endpoints remain essential.
Enobosarm has also been investigated in androgen receptor positive breast cancer. This represents a different research application based on tumour biology rather than muscle development. Findings from oncology studies cannot be transferred directly to healthy muscle models, but they reinforce the fact that androgen receptor modulation has wider biological implications than commercial descriptions of Ostarine often suggest.
AC-262 Accadrine and Partial Agonist Research
AC-262 is more precisely called AC-262,536. It was identified through functional cellular screening as a potent androgen receptor ligand with partial agonist activity relative to testosterone.
A partial agonist can bind to and activate a receptor without producing the same maximum response as a full agonist in a particular experimental system. This does not mean that a partial agonist is automatically weak, safe or inactive. The result depends on the assay, receptor density, tissue, exposure and regulatory proteins present in the cell.
The principal 2008 study examined AC-262,536 in cellular assays and a two week experiment using castrated male rats. The researchers reported changes in anabolic measurements, including increased levator ani muscle weight, together with suppression of elevated luteinising hormone. Effects on prostate and seminal vesicle weights were lower than those produced by testosterone under the reported conditions.
These findings supported further interest in tissue selective androgen receptor modulation. They did not establish that AC-262 affects humans in the same way. The levator ani assay is a traditional preclinical method for comparing anabolic and androgenic activity, but it does not reproduce the complexity of human skeletal muscle, endocrine regulation or long term exposure.
The suppression of luteinising hormone is also important. It shows that tissue selectivity should not be confused with isolation from endocrine feedback. A compound can produce a different ratio of responses across measured tissues while still influencing the hypothalamic pituitary gonadal system.
There are no robust controlled human trials establishing the effects, pharmacokinetics or long term safety of AC-262,536. Commercial statements about muscle growth, fat loss, strength or reduced adverse effects therefore extend beyond the published evidence. AC-262 remains primarily a preclinical research compound with an interesting receptor profile but substantial unanswered questions.
ACP-105 Androxepen Research
ACP-105 was discovered through a medicinal chemistry programme investigating new nonsteroidal androgen receptor ligands. A 2009 publication described ACP-105 as a potent selective androgen receptor modulator with partial agonist activity relative to testosterone.
The compound emerged from high throughput screening using receptor selection and amplification technology. Researchers then refined related chemical structures and evaluated their activity. In a two week study involving castrated male rats, ACP-105 was reported to improve selected anabolic measurements.
This provides evidence that ACP-105 can produce androgen receptor associated activity in laboratory and animal systems. It does not establish effects in humans. No substantial body of controlled human research has characterised its pharmacokinetics, effective exposure, endocrine consequences or long term safety.
ACP-105 has also appeared in specialised animal research involving neurological endpoints. One study examined the compound in a transgenic mouse model associated with Alzheimer type pathology, both alone and with the selective oestrogen receptor beta agonist AC-186. Reported behavioural and biochemical observations generated research interest, but the combined condition makes it difficult to attribute every result to ACP-105 independently.
A mouse model cannot reproduce the complete biology or clinical progression of human neurodegenerative disease. These studies should therefore be understood as exploratory receptor research rather than evidence that ACP-105 improves human memory or treats cognitive decline.
More recent analytical and computational work has examined the metabolism, detection and predicted disposition of ACP-105. These studies can help laboratories identify the parent compound and possible metabolites, but computational predictions are not equivalent to measured human pharmacokinetics or clinical safety data.
How the Three Compounds Differ
The clearest difference within this set is evidence maturity. MK-2866 has completed controlled human investigations, although the results are not uniformly positive and the compound has not been established as an approved muscle building treatment. AC-262 and ACP-105 are supported mainly by receptor assays, medicinal chemistry research and short animal experiments.
Their structural differences are also scientifically important. All three compounds are nonsteroidal androgen receptor ligands, but they do not share the same complete chemical scaffold. Different structures can alter binding, receptor conformation, metabolism, tissue exposure and the transcriptional response produced after receptor activation.
MK-2866 provides the most useful human research reference within the set. AC-262 introduces a distinct ligand with reported partial agonist behaviour and a preclinical pattern of anabolic and reproductive tissue measurements. ACP-105 provides another structurally separate partial agonist originating from a related discovery programme.
None of these distinctions proves that one compound is universally stronger or safer. Comparisons based on quantities printed on a capsule label are particularly unreliable because milligrams do not measure receptor potency, systemic exposure or biological effect. A lower mass of one compound cannot be assumed to equal a higher mass of another.
Does the Set Have a Muscle Research Rationale?
The set has a legitimate comparative connection to muscle research because the androgen receptor contributes to the regulation of skeletal muscle biology. MK-2866 has been investigated using human lean body mass and physical function endpoints, while AC-262 and ACP-105 have been studied through preclinical anabolic measurements.
That shared theme does not establish that combining all three compounds produces a greater muscle response. Compounds competing for or activating the same receptor can generate complex results. One ligand may alter the apparent activity of another, different pharmacokinetic profiles may change receptor exposure over time and downstream transcription may not increase in a simple additive manner.
No strong published head to head study has compared MK-2866, AC-262 and ACP-105 under matched conditions. There is also no controlled evidence demonstrating synergy among the three compounds. The scientifically responsible position is therefore to describe a common research pathway without claiming a proven combined outcome.
A well controlled investigation would first characterise each compound independently. Measurements could then be compared using the same cellular system, exposure period, analytical method and receptor dependent endpoint. Combined conditions would only become interpretable after the independent concentration response relationships had been established.
Receptor Binding Is Not the Same as Muscle Growth
Commercial discussions often move directly from androgen receptor binding to claims about muscle growth. Several experimental stages are missing from that assumption.
A binding assay can show that a molecule interacts with the androgen receptor. A functional cellular assay can determine whether that interaction activates or inhibits a measured receptor response. Gene expression analysis can identify downstream transcriptional changes. Cell and tissue models can then investigate protein synthesis, differentiation, morphology or functional behaviour.
Animal studies add information about absorption, metabolism, tissue distribution, endocrine feedback and whole organism responses. Human trials are required to determine whether those observations translate into meaningful changes in body composition, strength, physical performance or clinical outcome.
MK-2866 has progressed through more of these stages than AC-262 or ACP-105. Even for MK-2866, however, increases in lean mass have not always produced consistent improvements in physical function. This is direct evidence that receptor activity, lean tissue measurements and useful functional outcomes cannot be treated as interchangeable concepts.
Endocrine and Safety Considerations
A compound described as tissue selective can still influence hormone feedback, lipid measurements, liver markers, reproductive tissues and other androgen responsive systems. The available human research on MK-2866 provides more safety information than is available for AC-262 or ACP-105, but it does not establish unrestricted safety or validate exposure outside the studied protocols.
The human MK-2866 literature has reported changes in measurements such as sex hormone binding globulin, testosterone in male participants, high density lipoprotein cholesterol and liver enzymes under particular study conditions. These findings need to be interpreted according to quantity, duration, participant characteristics and baseline health.
For AC-262 and ACP-105, the absence of a large human adverse event dataset should not be interpreted as evidence of fewer adverse effects. It primarily reflects the absence of adequate trials. Unknown risk is not the same as demonstrated safety.
Selective androgen receptor modulators are prohibited in competitive sport. UK Anti Doping states that SARMs have been banned by the World Anti Doping Agency since 2008 and are listed as anabolic agents. This applies regardless of whether a compound is presented as a research chemical, supplement or experimental pharmaceutical.
None of the three compounds should be described as an approved supplement or established treatment for increasing muscle mass. Their inclusion in scientific publications does not confer regulatory approval, and early research findings do not establish suitability for personal use.
Why Evidence Cannot Be Transferred Between SARMs
The larger MK-2866 evidence base cannot be used to fill gaps in the AC-262 or ACP-105 literature. Each molecule requires its own pharmacological and toxicological assessment.
Even closely related compounds can differ in absorption, protein binding, metabolic stability, active metabolites, elimination and access to different tissues. A result reported for Enobosarm cannot establish an equivalent outcome for Accadrine. Findings from AC-262 cannot establish the behaviour of ACP-105.
This distinction is particularly important when evaluating commercial descriptions. Grouping all three compounds under the SARM category is chemically useful, but it does not provide evidence that they share the same potency, selectivity, duration, adverse effect profile or research outcome.
The same restriction applies to safety. A tolerated exposure in a short MK-2866 trial cannot establish the safety of an untested AC-262 or ACP-105 exposure. Preclinical tissue ratios also cannot guarantee tissue selectivity in humans.
Laboratory Identity and Analytical Testing
Research quality begins with confirming that each material contains the compound stated on its label. This is especially important in a three product set because an unidentified or incorrectly quantified component can undermine the entire comparison.
High performance liquid chromatography can evaluate chromatographic purity and reveal the proportion of detected material represented by the principal peak. Mass spectrometry can help determine whether the measured mass is consistent with the expected compound. When stronger structural confirmation is required, laboratories may also use nuclear magnetic resonance spectroscopy and appropriate reference standards.
These methods answer different questions. A high chromatographic purity percentage does not independently prove molecular identity. A mass consistent with the expected molecule does not establish quantity, biological activity or the absence of every possible impurity. Capsule research also introduces questions about content uniformity, excipients and whether the stated amount is present consistently across individual units.
A certificate of analysis should be linked clearly to the relevant product or batch. Researchers should examine the sample identification, laboratory name, analytical method, testing date, reported result and batch information rather than relying only on a prominent purity percentage.
The three compounds should remain analytically distinguishable. MK-2866, AC-262,536 and ACP-105 possess different molecular structures and expected analytical behaviour. A credible comparative programme should confirm each identity before investigating receptor activity or downstream biological endpoints.
Designing a Meaningful Three Compound Comparison
The strongest research design would avoid beginning with all three compounds in one combined condition. Each compound should first be evaluated separately against the same vehicle control and a properly characterised androgen receptor reference ligand.
Androgen receptor dependence could be examined using a validated receptor antagonist, receptor knockdown or a suitable comparison between receptor expressing and receptor deficient systems. This would help determine whether an observed response is genuinely mediated through the androgen receptor rather than an unrelated cellular pathway.
Concentration response relationships are more informative than a single arbitrary exposure. Researchers should measure receptor activation alongside cell viability so that apparent changes are not confused with general cytotoxicity. Downstream gene expression should be supported by protein or functional measurements where possible.
A muscle cell programme could examine early myogenic markers, later differentiation markers, myotube morphology and functional characteristics. Changes in one gene should not be presented as proof of muscle formation. Animal research would require pharmacokinetic measurements, tissue exposure, endocrine markers, liver and lipid assessments, reproductive observations and histology.
Only after each compound had been characterised independently would a combined condition become scientifically interpretable. Even then, evidence of synergy would require a predefined quantitative model showing that the combined response exceeds the expected additive response. A larger result in a mixture is not automatically synergy.
Evidence Strength and Important Limitations
MK-2866 has the strongest evidence within the set because it has been evaluated in controlled human trials. Those trials provide useful body composition, functional, endocrine and safety observations, but they have not established the compound as a general muscle building treatment. Clinical development has also shown that improvements in lean mass do not guarantee consistent improvements in physical function.
AC-262 has a much smaller evidence base dominated by one principal pharmacological study involving cellular assays and castrated rats. ACP-105 has medicinal chemistry, receptor and animal research behind it, together with specialised neurological studies, but lacks robust controlled human evidence.
Direct comparison is limited because the compounds have not been studied together using the same concentrations, models and endpoints. Apparent differences drawn from separate publications may reflect study design rather than genuine superiority.
There is no reliable basis for claiming that this three compound set produces confirmed synergy. There is also insufficient evidence to rank the compounds by human safety. The absence of reported human problems for AC-262 or ACP-105 mainly reflects the absence of adequate human investigation.
Conclusion
MK-2866, AC-262 and ACP-105 are three distinct nonsteroidal selective androgen receptor modulators connected by a common molecular research theme. They provide a useful framework for comparing how different chemical structures interact with androgen receptor signalling, but they do not represent interchangeable compounds.
MK-2866 has the most developed evidence base and has produced measurable changes in lean body mass and selected functional outcomes within controlled human research. Its later clinical development also demonstrates why body composition changes must be separated from reliable improvements in physical function.
AC-262,536 has been characterised as a partial androgen receptor agonist and has produced anabolic and endocrine effects in short animal experiments. ACP-105 has also demonstrated partial agonist activity and preclinical anabolic responses, but its human pharmacology remains insufficiently characterised.
The set is therefore best understood as a three way androgen receptor research comparison. Its value lies in examining differences in receptor activation, tissue response, evidence maturity and analytical identity. No published evidence currently proves that combining MK-2866, AC-262 and ACP-105 creates synergy, improves outcomes or reduces risk.
Continue Exploring...
MK-2866, AC-262 and ACP-105 Research Set
View the BioPlex Selective Androgen Pathway Research Set ⟶
AC-262 vs MK-2866 Research Comparison
Read the BioPlex AC-262 vs Ostarine MK-2866 research comparison ⟶
ACP-105 Androxepen Research Overview
Explore ACP-105 androgen receptor research and current evidence ⟶
SARMs Research Sets
Explore BioPlex SARMs research sets and compound combinations ⟶
SARMs Research Articles
Read BioPlex SARMs research articles and scientific study guides ⟶
Research Product Testing
View BioPlex independent product testing information ⟶
All discussion is presented strictly for educational and scientific research purposes only, supporting informed study, data interpretation, and responsible laboratory investigation.
